Ibrexafungerp: A novel oral glucan synthase inhibitor

Davis, M R; Donnelley, M A; Thompson, G R

doi:10.1093/mmy/myz083

Cited by 91Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal and yeast genetics research

Ibrexafungerp: A novel oral glucan synthase inhibitor

Davis, M R, Donnelley, M A, Thompson, G R·2020·Medical Mycology

DOI 10.1093/mmy/myz083

Open this paper in CoChat — free account

Abstract

Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp. It is able to retain activity against many echinocandin-resistant strains of Candida due to differential avidity for the target site compared to echinocandins. In vivo animal models have demonstrated efficacy in murine models of invasive candidiasis, aspergillosis, and pneumocystis. Due to high bioavailability, it can be administered both orally and intravenously. A favorable drug interaction and tolerability profile is observed with this compound. This review summarizes existing data that have either been published or presented at international symposia.

Integrity signals

Registry

Crossref · 10.1093/mmy/myz083

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Ibrexafungerp has potent in vitro activity against clinically relevant Aspergillus species.
“Against Aspergillus clinically relevant species, ibrexafungerp has also demonstrated potent in vitro activity (Davis et al., 2019).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Davis et al., 2019
Ibrexafungerp's spectrum of activity includes highly resistant Candida, Cryptococcus species, Aspergillus species, and endemic fungi.
“It is anticipated to advance the treatment of highly resistant Candida infections; however, its spectrum of activity also includes Cryptococcus species, Aspergillus species, and endemic fungi (Fig. 1) [20].”
From Investigational Agents for the Treatment of Resistant Yeasts and Molds (2021) · cites this paper as [20]
IBX can be given orally with a favorable safety profile.
“IBX introduces a novel mechanism, potent broad spectrum of activity and a safe oral formulation”
From Investigational Agents for the Treatment of Resistant Yeasts and Molds (2021) · cites this paper as [20]
IBX acts through a mechanism not previously used by antifungals.
“IBX introduces a novel mechanism, potent broad spectrum of activity and a safe oral formulation”
From Investigational Agents for the Treatment of Resistant Yeasts and Molds (2021) · cites this paper as [20]

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1
Artursson, P., Palm, K., & Luthman, K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00128-9 · Cited by 1,549 · see citing works
Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298 · see citing works
Anidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894 · see citing works
Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · see citing works
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · see citing works
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541 · see citing works
Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial
Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., Heinz, W. J., Jagannatha, S., Koh, L. P., Kontoyiannis, D. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m13-2508 · Cited by 514 · see citing works
Combination Polyene‐Caspofungin Treatment of Rhino‐Orbital‐Cerebral Mucormycosis
Reed, C., Bryant, R. E., Ibrahim, A. S., Edwards, J. E., Filler, S. G., Goldberg, R. A., & Spellberg, B. J. (2008) · Clinical Infectious Diseases · doi:10.1086/589857 · Cited by 491 · see citing works
The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation
Larkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02396-16 · Cited by 395 · see citing works
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R. E., Lewis, J. S., Martin, C. A., & Andes, D. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 311 · see citing works
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226 · see citing works
Echinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213 · see citing works
Paradoxical Effect of Echinocandins across Candida Species In Vitro: Evidence for Echinocandin-Specific and Candida Species-Related Differences
Chamilos, G., Lewis, R. E., Albert, N., & Kontoyiannis, D. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00095-07 · Cited by 171 · see citing works
Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma
Stone, J. A., Xu, X., Winchell, G. A., Deutsch, P., Pearson, P. G., Migoya, E. M., Mistry, G. C., Xi, L., Miller, A. R., Sandhu, P., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.815-823.2004 · Cited by 138 · see citing works
Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates
Jiménez‐Ortigosa, C., Paderu, P., Motyl, M. R., & Perlin, D. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02145-13 · Cited by 122 · see citing works
Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia
Andes, D. R., Ambrose, P. G., Hammel, J., Wart, S. A. V., Iyer, V., Reynolds, D. K., Buell, D. N., Kovanda, L. L., & Bhavnani, S. M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01430-10 · Cited by 119 · see citing works
In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris
Berkow, E. L., Angulo, D. A., & Lockhart, S. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00435-17 · Cited by 103 · see citing works
Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates
Lamoth, F., & Alexander, B. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00234-15 · Cited by 100 · see citing works
Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks466 · Cited by 99 · see citing works
In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98 · see citing works
Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model
Lepak, A. J., Marchillo, K., & Andes, D. R. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04445-14 · Cited by 95 · see citing works
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
Wring, S. A., Randolph, R., Park, S., Abruzzo, G. K., Chen, Q., Flattery, A. M., Garrett, G. C., Peel, M. R., Outcalt, R. J., Powell, K. D., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02068-16 · Cited by 94 · see citing works
De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance
Jiménez-Ortigosa, C., Perez, W. B., Angulo, D., Borroto-Esoda, K., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-17 · Cited by 89 · see citing works
SCY-078 is fungicidal against Candida species in time-kill studies
Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., & Wring, S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01961-16 · Cited by 88 · see citing works
Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84 · see citing works
Evaluation of the antifungal activity of the novel Oral Glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis
Ghannoum, M., Long, L., Larkin, E. L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., & Angulo, D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00244-18 · Cited by 80 · see citing works
Discovery of a Novel Class of Orally Active Antifungal β-1,3- <scp>d</scp> -Glucan Synthase Inhibitors
Walker, S. S., Xu, Y., Triantafyllou, I., Waldman, M. F., Mendrick, C., Brown, N., Mann, P., Chau, A., Patel, R., Bauman, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00432-11 · Cited by 75 · see citing works
Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species
Schell, W. A., Jones, A. M., Borroto-Esoda, K., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-17 · Cited by 66 · see citing works
Clinical Pharmacokinetics and Drug‐Drug Interaction Potential for Coadministered SCY‐078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus
Wring, S. A., Murphy, G. M., Atiee, G. J., Corr, C., Hyman, M., Willett, M. S., & Angulo, D. A. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.588 · Cited by 45 · see citing works
SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [ 14 C]SCY-078 in Albino and Pigmented Rats
Wring, S. A., Borroto–Esoda, K., Solon, E. G., & Angulo, D. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02119-18 · Cited by 45 · see citing works
The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp
Marcos-Zambrano, L. J., Gómez-Perosanz, M., Escribano, P., Bouza, E., & Guinea, J. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx010 · Cited by 44 · see citing works
Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Pizzini, J., Catano, G., & Patterson, T. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx422 · Cited by 43 · see citing works
Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions
Wring, S. A., Murphy, G. M., Atiee, G. J., Corr, C., Hyman, M., Willett, M. S., & Angulo, D. A. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1146 · Cited by 39 · see citing works
Activity of a Novel 1,3-Beta- d -Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata
Ghannoum, M. A., Long, L., Isham, N. C., Hager, C. L., Wilson, R. A., Borroto–Esoda, K., Barat, S., & Angulo, D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01510-19 · Cited by 31 · see citing works
SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
Borroto–Esoda, K., Barat, S., Angulo, D. A., Holden, K. A., & Warn, P. A. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1207 · Cited by 17 · see citing works

Flagged first, then by citations

Sorted by citations

Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801 · see citing works
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · see citing works
Self-citation
Fungal Cell Wall: Emerging Antifungals and Drug Resistance.
Lima, S. L., Colombo, A. L., & de Almeida Junior, J. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02573 · Cited by 223 · see citing works
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225 · see citing works
Self-citation
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129 · see citing works
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
Gamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642358 · Cited by 58 · see citing works
Oral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis
Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791820 · Cited by 46 · see citing works
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · see citing works

Echinocandin Antifungal Drug Resistance in Candida Species: A Cause for Concern?
Sanguinetti, M., Posteraro, P., & Posteraro, B. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0131-2 · Cited by 16 · see citing works
Critical Assessment of Cell Wall Integrity Factors Contributing to in vivo Echinocandin Tolerance and Resistance in Candida glabrata
Garcia-Rubio, R., Hernandez, R. Y., Clear, A., Healey, K. R., Shor, E., & Perlin, D. S. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.702779 · Cited by 35 · see citing works
Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?
Fekkar, A., Dannaoui, É., Meyer, I., Imbert, S., Brossas, J., Uzunov, M., Mellon, G., Nguyen‐Quoc, S., Guiller, E., Caumes, É., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2096-9 · Cited by 63 · see citing works
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review
Sun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 66 · see citing works
Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins
Hori, Y., & Shibuya, K. (2018) · Medical Mycology Journal · doi:10.3314/mmj.18.004 · Cited by 28 · see citing works

Authors: Davis, M. R., Donnelley, M. A., & Thompson, G. R.
Affiliations: University of California Davis Medical Center (US)
Corresponding author: Davis, M R
Thompson, G R
ORCID: Davis, M R
Donnelley, M A
Thompson, G R
Venue: Medical Mycology
Publisher: Oxford University Press (OUP)
Published: 2019-07-25
Volume: 58
Issue: 5
Pages: 579-592
ISSN: 0268-1218 (ISSN-L)
1369-3786
1460-2709
DOI: 10.1093/mmy/myz083
OpenAlex: W2962990120
Cited by: 91
References: 36
Citations by year: 2026: 4 · 2025: 10 · 2024: 11 · 2023: 9 · 2022: 21 · 2021: 22 · 2020: 12 · 2019: 2
FWCI: 1.99
Type: journal article
Language: en
Open access: closed
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: Medical Mycology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords: ibrexafungerp, antifungal agents, Candida, Aspergillus, echinocandin resistance, invasive candidiasis, aspergillosis, Pneumocystis carinii pneumonia, oral antifungal therapy, bioavailability, drug interactions, tolerability
MeSH terms: Animals, Antifungal Agents, Aspergillus, Azoles, Candida, Disease Models, Animal, Enzyme Inhibitors, Glucosyltransferases, Glycosides, Humans, Triterpenes, Biofilms, Drug Resistance, Fungal, Mice, Echinocandins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ibrexafungerp: A novel oral glucan synthase inhibitor

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks